MedTrace Logo

Finding Retinal Biomarkers in Alzheimer's Disease

NCT05067010 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 93

Last updated 2025-04-08

No results posted yet for this study

Summary

CSF Alzheimer's disease (AD) biomarkers are the only one that reflect both Aβ and tau pathologies. There is increasing evidence for the presence of AD abnormalities in the retina of AD patients. Recent studies showed that they can be detected in living patients. Thus, retinal AD-linked abnormalities might be used as alternative diagnostic biomarkers for AD.

FIREBALZ study aims at identifying and validating retinal biomarkers for the diagnosis of Alzheimer's disease.

The study will include 160 patients in whom LP is indicated for assessment of CSF AD biomarkers according to French health authority (HAS) recommendations. Those patients will undergo a detailed neuro-ophtalmologic evaluation including retinal layers thickness evaluation (optical coherence tomography).

Univariate and multivariate analyses will be performed to test diagnostic properties of retinal parameters as compared to current diagnostic criteria including CSF biomarkers and logistic regression models will be used.

Conditions

  • Alzheimer Disease

Interventions

OTHER

Detailed ophthalmologic examination

* Visual acuity * Eye pressure measurement * Eye crystalline examination * Fundus examination * Optical coherence tomography of the retina * Retinophotos

Sponsors & Collaborators

  • Assistance Publique - Hôpitaux de Paris

    lead OTHER

Principal Investigators

  • Emmanuel COGNAT, Dr · Cognitive Neurology Center, CMRR Paris Nord Ile-De France

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-06-10
Primary Completion
2024-09-23
Completion
2024-12-24

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05067010 on ClinicalTrials.gov